An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

16505HLX43-NSCLC201-NCT06907615OpenAn Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)NCT06907615IndustrialAdultTreatmentIIGlobalLungLiu, StephenGeorgetown University Medical Center : Matt Hayhurst; Lombardi Comprehensive Cancer Center : Matt HayhurstThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC)16691Matt HayhurstMatt Hayhurstmh2340@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>